ISRCTN56087634进行中（未招募）2 期
A multicentre phase II study to investigate the feasibility and safety of high intensity focused ultrasound in the treatment of pancreatic cancer
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Histologically or cytologically confirmed adenocarcinoma
- •2. Locally advanced inoperable pancreatic ductal adenocarcinoma and or operable pancreatic ductal cancers but patients not fit for surgery
- •3. A measurable primary tumour on ultrasound imaging, with a target area of less than 8 cm in diameter on CT/MRI
- •4. A clear 1 cm margin between the tumour and associated organs (duodenum, stomach, transverse colon) on contrast-enhanced MR imaging
- •5. Biliary obstruction to be relieved before inclusion in the study
- •6. Age greater than or equal to 18 years
- •7. Fit for general anaesthesia
- •8. Performance status: ECOG =2
- •9. An American Society of Anaesthesiologists (ASA) grade of =3
- •10. Life expectancy: At least 12 weeks
- •11. Able to attend for long-term follow-up
- •12. No concurrent malignancy
- •13. No serious medical or psychological condition
- •14. Ability to give fully informed consent
排除标准
- •1. Patients with TNM Stage IV (metastatic disease)
- •2. Unclear cancer margins on ultrasound imaging
- •3. Invasion into the duodenal wall
- •4. Stricture of superior mesenteric artery directly by tumour encasement, or invasion of SMV below transverse mesocolon
- •5. Patient suitable for surgical resection
- •6. Refusal to give informed consent
- •7. Unable to give informed consent
- •8. Not fit for HIFU treatment: any significant disease, disorder, or finding which, in the opinion of the investigator, may significantly increase the risk to the patient because of participation in the study
- •9. Active or ongoing infection requiring IV antibiotics
- •10. Known pregnancy
研究者
相似试验
招募中
2 期
WALCURE trialPatients who diagnosed pancreatic cancer with positive for peritoneal washing cytologypancreatic cancer, peritoneal washing cytologyJPRN-jRCTs041230019Tsutomu Fujii208
进行中（未招募）
1 期
A study evaluating the safety and efficacy of 19CP02 in subjects with non-Hodgkin lymphomaRelapsed/refractory B-cell non-Hodgkin lymphomaMedDRA version: 20.0Level: HLGTClassification code 10025320Term: Lymphomas non-Hodgkin's B-cellSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2021-003272-13-NLCellPoint B.V.45
进行中（未招募）
1 期
A study evaluating the safety and efficacy of 19CP02 in subjects with non-Hodgkin lymphomaEUCTR2021-003272-13-BECellPoint B.V.45
进行中（未招募）
1 期
A study evaluating the safety and efficacy of GLPG5101 (19CP02) in subjects with non-Hodgkin lymphomaCTIS2022-502661-23-00Galapagos40
招募中
不适用
A phase I/II, multicenter study evaluating the feasibility, safety, and efficacy of point-of-care manufactured 19CP02 in subjects with relapsed/refractory B-cell non-Hodgkin lymphomacancer of the lymphatic system10025320LymphomaNL-OMON51902CellPoint B.V.15